Detalhe da pesquisa
1.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139274
2.
AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.
Br J Cancer
; 130(8): 1249-1260, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361045
3.
Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
Mod Pathol
; 37(4): 100445, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38341130
4.
PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms.
Mod Pathol
; 37(4): 100442, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38309431
5.
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
Strahlenther Onkol
; 2024 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38393398
6.
Matrix stiffness drives stromal autophagy and promotes formation of a protumorigenic niche.
Proc Natl Acad Sci U S A
; 118(40)2021 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34588305
7.
The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
Breast Cancer Res
; 25(1): 32, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36978142
8.
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med
; 382(9): 810-821, 2020 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32101663
9.
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging.
Int J Mol Sci
; 24(3)2023 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36769215
10.
mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease.
Int J Cancer
; 150(8): 1357-1372, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34927257
11.
pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas-proposal for a new pT3a/pT3b subclassification.
Br J Cancer
; 127(7): 1270-1278, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35864156
12.
Breast cancer.
Lancet
; 397(10286): 1750-1769, 2021 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33812473
13.
Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.
Cancer Immunol Immunother
; 71(10): 2381-2389, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35184226
14.
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
Breast Cancer Res Treat
; 191(2): 327-333, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34783927
15.
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
BMC Cancer
; 22(1): 1040, 2022 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36195836
16.
Increasing the efficiency of hyperthermic intraperitoneal chemotherapy (HIPEC) by combination with a photosensitive drug in pediatric rhabdomyosarcoma in an animal model.
Pediatr Blood Cancer
; 69(11): e29864, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731577
17.
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Lancet Oncol
; 22(8): 1151-1161, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34252375
18.
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox.
Lancet Oncol
; 22(1): e18-e28, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387500
19.
Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.
Breast Cancer Res
; 23(1): 1, 2021 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33407744
20.
A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
Histopathology
; 78(4): 567-577, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32936950